Back to Markets
NMNeumora Therapeutics Inc

Neumora Therapeutics Inc

NMRANASDAQ NMS - GLOBAL MARKET
Health CarePharmaceuticals

$1.85

-0.030000 (-1.60%)

As of 05/29/26 EDT · USD

Compare
Low: $0.6900Current: $1.85High: $3.65

Key Statistics

Open

$1.89

Day High

$1.96

Day Low

$1.85

Prev. Close

$1.88

VolumeShares traded today.

884.87K

Avg. VolumeAverage daily volume.

Market CapTotal value of all shares = price × shares outstanding.

$342.78M

P/E (TTM)Price-to-Earnings: share price ÷ earnings per share over the last 12 months. Lower can mean cheaper; very high can mean growth expectations.

-1.39

Forward P/EP/E based on forecast next-year earnings.

P/B RatioPrice-to-Book: share price ÷ book value per share.

52W HighHighest price over the past 52 weeks.

$3.65

52W LowLowest price over the past 52 weeks.

$0.6900

50D MAAverage closing price over the last 50 trading days.

$2.11

200D MAAverage closing price over the last 200 trading days.

$2.20

Dividend YieldAnnual dividend ÷ share price, as a %.

BetaVolatility vs the market. >1 = more volatile than the S&P 500.

Performance

1W

+0.0%

1M

-17.8%

6M

-17.8%

YTD

+11.4%

1Y

+147.4%

About

Navacaprant is a selective κ-opioid receptor (KOR) antagonist which is under development for the treatment of major depressive disorder and bipolar depression. It was originated by BlackThorn Therapeutics and is being developed by Neumora Therapeutics. As of February 2025, navacaprant is in phase 3 clinical trials for major depressive disorder. In January 2025, it was disclosed that navacaprant had failed to show effectiveness for major depressive disorder in a phase 3 trial. Upon this announcement, the stock price of Neumora Therapeutics decreased by 80%.

neumoratx.com/

Company Facts

SectorHealth Care
IndustryPharmaceuticals
ExchangeNASDAQ NMS - GLOBAL MARKET
CurrencyUSD

Sentiment

Latest News

Social Noise

Price Alerts

Loading…

Trade NMRA

Brokers available in your region (US)

Affiliate links — we may earn a commission. CFDs are risky.